Tagged with Chiesi

Global 2023 was a tumultuous year for the pharma industry, with much wailing and gnashing of teeth from executives over the Inflation Reduction Act in the US as well as updated EU pharma legislation in Europe. Those companies producing COVID-19 vaccines and therapeutics saw revenues return to normal levels while others…

Italy The latest Italy Pharma News, including the government’s decision to make COVID-19 vaccines mandatory for all healthcare workers, the manufacturing of Sputnik V, and recent updates from the country’s top companies, including Chiesi, Angelini Pharma and Menarini.   Doses of Russia’s Sputnik V, made in Italy, to go on sale…

Italy A roundup of some of the most important recent stories from Italian pharma, including an in-depth interview with Menarini CEO Elcin Barker Ergun, a public health management crisis in the south of the country, Chiesi’s latest mobile health partnership, and the potential rollout of COVID-19 vaccines in January 2021.  …

Italy Italy’s pharma industry consistently ranks among the top 10 globally, with domestic companies making up a significant share. These, largely private family-owned firms also have an increasingly global footprint, with international operations now making up a larger portion of their revenues than ever before. See below for the top six…

Belgium Geert Van Hoof, founding general manager of Chiesi Belgium, shares the exciting milestones of the company’s first decade in Belgium, including their stunning year-on-year double-digit growth, their market leadership in respiratory as well as neonatology, and their growing presence in rare diseases, as well as the attractiveness of the Chiesi…

Mexico Earlier in 2020, PharmaBoardroom sat down with several key stakeholders in the Mexican healthcare and life sciences industry, from the leaders of multinational affiliates, start-up entrepreneurs, association heads, and key opinion leaders. Here, we round up three of their most talked about topics.   Government  One of the most talked-about…

Mexico Chiesi Mexico’s Marco Ruggiero discusses his initial impressions of the Mexican pharma market, his strategic priorities for the affiliate, and the increasing importance of the company’s respiratory portfolio in Mexico.   With respiratory diseases, there is sometimes the erroneous perception that they are not as severe or urgent as other…

Italy Italian mid-cap firm Chiesi is continuing its expansion in the USA market with the launch of a Boston-based subsidiary focusing on rare and ultra-rare diseases.   We are very excited to put Chiesi’s decades of experience in drug development and dedication to patients to work to make a positive difference…

Sweden Olav Fromm, managing director of Chiesi Nordics, explains the deep roots of Chiesi in Sweden, where its blockbuster drug, a surfactant for treating neonatal babies, was developed. He also touches upon the strategic importance of the region to Chiesi, with the recent creation of a fully-fledged Nordic subsidiary, which will…

China This is the first in a series of articles examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. We start in China, where the heads of Merck, Ipsen, Chiesi, Gedeon Richter and AbbVie’s Chinese affiliates give their…

China Davide Dalle Fusine, general manager for Chiesi China, shares the key milestones for the company in the past five years, their leadership position in neonatology and strength respiratory franchise in China, the importance of the Chinese market for global operations, as well as his strategic priorities for the next few…

Spain Giuseppe Chiericatti of Chiesi Spain talks strategy, the development of the affiliate and shifting attitudes towards rare diseases in Spain.   Social responsibility and sustainability is a key part of our mission. Our goal is to integrate the concept of sustainability in whatever we do You’ve been leading the Spanish…